Comprehensive Psychiatry
Volume 49, Issue 2 , Pages 170-176 , March 2008

Correlations of attitudes toward antipsychotic drugs with insight and objective psychopathology in schizophrenia

References 

  1. Naber D, Karow A. Good tolerability equals good results: the patient's perspective. Eur Neuropsychopharm. 2001;11(4):S391–S396
  2. Fenton WS, Blyler CR, Heinssen RK. Determinants of medication compliance in schizophrenia: empirical and clinical findings. Schizophr Bull. 1998;23:637–651
  3. Garavan J, Browne S, Gervin M, Lane A, Larkin C, O'Callaghan E. Compliance with neuroleptic medication in outpatients with schizophrenia; relationship to subjective response to neuroleptics; attitudes to medication and insight. Compr Psychiatry. 1998;39:215–219
  4. Marder SR. Facilitating compliance with antipsychotic medication. J Clin Psychiatry. 1998;59(3):21–25
  5. Lacro JP, Dunn LB, Dolder CR, Leckband SG, Jeste DV. Prevalence of end risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry. 2002;63:892–909
  6. Amador XF, Gorman JM. Psychopathologic domains and insight in schizophrenia. Psychiatr Clin North Am. 1998;21(1):27–42
  7. De Millas W, Lambert M, Naber D. The impact of subjective well-being under neuroleptic treatment on compliance and remission. Dialogues Clin Neurosci. 2006;8:131–136
  8. Smith TE, Hull JW, Goodman M, Hedayat-Harris A, Willson DF, Israel LM, et al. The relative influences of symptoms, insight, and neurocognition on social adjustment in schizophrenia and schizoaffective disorder. J Nerv Ment Dis. 1999;187(2):102–108
  9. Loffler W, Kilian R, Toumi M, Angermeyer MC. Schizophrenic patients' subjective reasons for compliance and noncompliance with neuroleptic treatment. Pharmacopsychiatry. 2003;36:105–112
  10. Hofer A, Kemmler G, Eder U, Honeder M, Hummer M, Fleischhacker WW. Attitudes toward antipsychotics among outpatient clinic attendees with schizophrenia. J Clin Psychiatry. 2002;63:49–53
  11. Kim JH, Kim SY, Ahn YM, Kim YS. Subjective response to clozapine and risperidone treatment in outpatients with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2005;30(2):301–305
  12. Naber D, Karow A, Lambert M. Subjective well-being under the neuroleptic treatment and its relevance for compliance. Acta Psychiatr Scand. 2005;427:29–34
  13. Hogan TP, Awad AG. Subjective response to neuroleptics and outcome in schizophrenia: a re-examination comparing two measures. Psychol Med. 1992;22(2):347–352
  14. Naber D. A self-rating to measure subjective effects of neuroleptic drugs, relationships to objective psychopathology, quality of life, compliance and other clinical variables. Int Clin Psychopharmacol. 1995;10(3):133–138
  15. Voruganti K, Heslegrave RJ, Awad AG, Seeman M. Quality of life measurement in schizophrenia: reconciling the quest for subjectivity with the question of reliability. Psychol Med. 1998;28(1):165–172
  16. Lambert M, Graf Schimmelmann B, Karow A, Naber D. Subjective well-being and initial disphoric reaction under antipsychotic drugs—concepts, measurement and clinical relevance. Pharmacopsychiatry. 2003;36:1–10
  17. Tempier R, Pawliuk N. Influence of novel and conventional antipsychotic medication on subjective quality of life. J Psychiatry Neurosci. 2001;26(2):131–136
  18. Voruganti L, Cortese L, Owyeumi L, Kotteda V, Cernovsky Z, Zirul S, et al. Switching from conventional to novel antipsychotic drugs: results of a prospective naturalistic study. Schizophr Res. 2002;57:201–208
  19. Draine J, Solomon P. Explaining attitudes toward medication compliance among a seriously mentally ill population. J Nerv Ment Dis. 1994;82(1):50–54
  20. Garcia Cabeza I, Sanz Amador M, Arango Lopez C, Gonzalez de Chavez M. Subjective response to antipsychotics in schizophrenic patients: clinical implications and related factors. Schizophr Res. 2000;21:349–355
  21. Gervin M, Browne S, Garavan J, Roe M, Larkin C, O'Callaghan E. Dysphoric subjective response to neuroleptics in schizophrenia: relationship to extrapyramidal side effects and symptomatology. Eur Psychiatry. 1999;14(7):405–409
  22. Norman RM, Malla AK, McLean T, Voruganti LP, Cortese L, McIntosh E, et al. The relationship of symptoms and level of functioning in schizophrenia to general well-being and the Quality of Life Scale. Acta Psychiatr Scand. 2000;102(4):303–309
  23. Ritsner M, Modai I, Endicott I. Differences in quality of life domains and psychopathologic and psychosocial factors in psychiatric patients. J Clin Psychiatry. 2000;61:880–889
  24. Karow A, Moritz S, Lambert M, Schoder S, Krausz M. PANSS syndromes and quality of life in schizophrenia. Psychopathology. 2005;38(6):320–326
  25. Putzhammer A, Perfahl M, Pfeiff L, Hajak G. Correlation of subjective well-being in schizophrenic patients with gait parameters, expert-rated motor disturbances, and psychopathological status. Pharmacopsychiatry. 2005;38(3):132–138
  26. Awad AG. Subjective response to neuroleptics in schizophrenia. Schizophr Bull. 1993;3:609–616
  27. De Haan L, Weisfelt M, Dingemans PM, Linszen DH, Wouters L. Psychometric properties of the Subjective Well-Being Under Neuroleptics Scale and the Subjective Deficit Syndrome Scale. Psychopharmacology. 2002;162(1):24–28
  28. Ritsner M, Kurs R, Gibel A. Predictors of quality of life in major psychoses: a naturalistic follow-up study. J Clin Psychiatry. 2003;64:308–315
  29. Giner J, Ibanez E, Cervera S, Sanmartin A, Caballero R. Subjective experience and quality of life in schizophrenia. Actas Esp Psiquiatr. 2001;29(4):233–242
  30. Naber D, Moritz S, Lambert M, Pajonk F, Holzbach R, Maas R, et al. Improvement in schizophrenic patients; subjective well-being under atypical antipsychotic drugs. Schizophr Res. 2001;50(1-2):79–88
  31. Rossi A, Arduini L, Stratta P, Pallanti S. Subjective experience and subjective response to neuroleptics in schizophrenia. Compr Psychiatry. 2000;41:446–449
  32. Sibitz I, Katschnig H, Goessler R, Unger A, Amering M. Pharmacophilia and pharmacophobia: determinants of patients' attitudes towards antipsychotic medication. Pharmacopsychiatry. 2005;38:107–112
  33. Kemp R, David A. Psychological predictors of insight and compliance in psychotic patients. Br J Psychiatry. 1996;169:444–450
  34. Freudenreich O, Cather C, Evins AE, Henderson DC, Goff DC. Attitudes of schizophrenia outpatients toward psychiatric medications: relationship to clinical variables and insight. J Clin Psychiatry. 2004;65(10):1372–1376
  35. Day JC, Bentall RP, Roberts C, Randall F, Rogers A, Cattell D, et al. Attitudes toward antipsychotic medication: the impact of clinical variables and relationships with health professionals. Arch Gen Psychiatry. 2005;62(7):717–724
  36. Garcia Cabeza I, Gomez JC, Sacristán JA, Edgell E, Gonzalez de Chavez M. Subjective response to antipsychotic treatment and compliance in schizophrenia. A naturalistic study comparing olanzapine, risperidone and haloperidol (EFESO Study). BMC Psychiatry. 2001;1:7
  37. Woods SW. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry. 2003;64(6):663–667
  38. Guy W. Clinical global impressions. In: In: ECDEU assessment manual for psychopharmacology (ADM 76-338). Rockville, MD: US Department of Health, Education and Welfare, National Institute for Mental Health; 1976;p. 217–222
  39. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13:261–276
  40. Addington D, Addington J, Schissel B. A depression rating scale for schizophrenics. Shizophr Res. 1990;3(4):247–251
  41. Endicott J, Spitzer RL. Schedule for Affective Disorders in Schizophrenia (SADS). Acta Psychiatr Belg. 1987;87(4):361–516
  42. Heinrichs DW, Hanlon TE, Carpenter WT. The Quality of Life Scale: an instrument for rating the schizophrenic deficit scale. Schizophr Bull. 1984;10:388–398
  43. Hogan TP, Award AG, Eastwood R. A self report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychol Med. 1983;13:177–183
  44. Amador XF, David AS. Insight and psychosis. New York: Oxford Univ. Press; 1998;
  45. Amador XF, Strauss DH, Yale SA, Flaum MM, Endicott J, Gorman JM. Assessment of insight in psychosis. Am J Psychiatry. 1993;150(6):873–879
  46. Awad AG, Hogan TP, Voruganti LN, Heslegrave RJ. Patients' subjective experiences on antipsychotic medications: implications for outcome and quality of life. Int Clin Psychopharmacol. 1995;10(3):123–132
  47. Goodman C, Knoll G, Isakov V, Silver H. Negative attitude towards medication is associated with working memory impairment in schizophrenia patients. Int Clin Psychopharmacol. 2005;20:93–96
  48. Kim SW, Shin IS, Kim JM, Yang SJ, Shin HY, Yoon JS. Association between attitude toward medication and neurocognitive function in schizophrenia. Clin Neuropharmacol. 2006;29:197–205
  49. Voruganti L, Cortese L, Oyewumi L, Cernovsky Z, Zirul S, Awad A. Comparative evaluation of conventional and novel antipsychotic drugs with reference to their subjective tolerability, side-effect profile and impact on quality of life. Schizophr Res. 2000;43(2-3):135–145
  50. Karow A, Schnedler D, Naber D. What would the patient choose? Subjective comparison of atypical and typical neuroleptics. Pharmacopsychiatry. 2006;39(2):47–51
  51. Ritsner M, Ponizovsky A, Endicott J, Nechamkin Y, Rauchverger B, Silver H, et al. The impact of side-effects of antipsychotic agents on life satisfaction of schizophrenia patients: a naturalistic study. Eur Neuropsychopharm. 2002;12(1):31–38
  52. Larsen EB, Gerlach J. Subjective experience of treatment, side-effects, mental state and quality of life in chronic schizophrenic out-patients treated with depot neuroleptics. Acta Psychiatr Scand. 1996;93(5):381–388
  53. Awad AG, Voruganti LN, Heslegrave RJ. A conceptual model of quality of life in schizophrenia: description and preliminary clinical validation. Qual Life Res. 1997;6(1):21–26
  54. Hofer A, Kemmler G, Eder U, Edlinger M, Hummer M, Fleischhacker WW. Quality of life in schizophrenia: the impact of psychopathology, attitude toward medication, and side effects. J Clin Psychiatry. 2004;65(7):932–939
  55. Trauer T, Duckmanton RA, Chiu E. A study of the quality of life of the severely mentally ill. Int J Soc Psychiatry. 1998;44(2):79–91
  56. Fitzgerald PB, Williams CL, Corteling N, Filia SL, Brewer K, Adams A, et al. Subject and observer-rated quality of life in schizophrenia. Acta Psychiatr Scand. 2001;103:387–392
  57. Melle I, Friis S, Haahr U, Johannesen JO, Larsen TK, Opjordsmoen S, et al. Measuring quality of life in first-episode psychosis. Eur Psychiatry. 2005;20:474–483
  58. Ruscher SM, de Wit R, Mazmanian D. Psychiatric patients' attitudes about medication and factors affecting noncompliance. Psychiatr Serv. 1997;48:82–85
  59. Gaebel W, Pietzcker A. One-year outcome of schizophrenic patients—the interaction of chronicity and neuroleptic treatment. Pharmacopsychiatry. 1985;18(3):235–239

PII: S0010-440X(07)00125-3

doi: 10.1016/j.comppsych.2007.08.013

Comprehensive Psychiatry
Volume 49, Issue 2 , Pages 170-176 , March 2008

Article Tools